Safety and efficacy of mirabegron and solifenacin in elderly patient with overactive bladder
Medycyna Faktów · 2021
DOI: 10.24292/01.mf.0121.6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medycyna Faktów, 2021. Verfasst von Tomasz Wiatr und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Lower urinary tract symptoms, including urgency, urgency incontinence, pollakiuria and nocturia are common in the elderly people and has significant impact on quality of life. Pharmacological treatment is recommended when conservative management, such as fluid intake normalization or bladder training, does not alleviate symptoms. Antimuscarinics were often used as the I line treatment for OAB, as these drugs block the activity of the muscarinic M2/M3 receptors in the bladder and provide a significant clinical benefit for OAB symptoms in the elderly people, but their side effects are common, often leading to treatment discontinuation. Mirabegron, a β3-adrenoceptor agonist, shows similar efficacy to antimuscarinic drugs without the risk of anticholinergic effects.
Zitieren
APA
Wiatr, T., & Chłosta, P. (2021). Safety and efficacy of mirabegron and solifenacin in elderly patient with overactive bladder. Medycyna Faktów. https://doi.org/10.24292/01.mf.0121.6
Vancouver
Wiatr T, Chłosta P. Safety and efficacy of mirabegron and solifenacin in elderly patient with overactive bladder. Medycyna Faktów. 2021. doi:10.24292/01.mf.0121.6
BibTeX
@article{Wiatr2021,
author = {Wiatr, Tomasz and Chłosta, Piotr},
title = {Safety and efficacy of mirabegron and solifenacin in elderly patient with overactive bladder},
journal = {Medycyna Faktów},
year = {2021},
doi = {10.24292/01.mf.0121.6}
}
EUVIMED